News About: Pharm. Industry
Pfizer Korea seeks its own sales force for combined product portfolio
As Hank McKinnell, chairman and chief executive officer of Pfizer Inc, said that its merger plan with Pharmacia Corporation will close during April of 2003, Pfizer Korea and Pharmacia Korea are stepping up their negot...
Drug advertising activities slow down due to recession.
The drug advertising activities showed under strict controls mainly due to the current economic recession and the government's drug price slashes.
The KPMA report shows the number of drug advertising preview durin...
Upper class drug companies targeting at 100 Billion Won of sales.
100 billion won of the sales is the most attractive target for most of ambitious drug companies to put their ultimate goals this year. It also implies a symbolic number for the upper class drug companies to pursue, in...
Drug makers of renowned brand items carve out bigger market share
Under the 80:20 rule originated from Vilfredo Pareto that a minority of input produces the majority of results, leading pharmaceutical manufacturers have witnessed a sharp increase of more than 15 percent in their mar...
Drug exports on the rising trend.
The drug exports in Jan. and Feb. this year rose significantly compared to the same period last year, showing a bright perspective.
According to the Korea Trade data the drug export in Feb. this year amounted to ab...
Fluoroquinolone Factive acquires approval from US FDAAn antibiotic "Factive" developed by a local drug manufacturer has obtained an approval from the US FDA for the first time in Korea.
LG Life Sciences said recently that Facti...
|
Additional indications of Factive probable
LG Life Sciences' Factive has received an approval letter from the US FDA as treatment against community-acquired pneumonia and acute exacerbation of chronic bronchitis, and penicillin-resistant S.pneumoniae (PRSP), e...
Handok-Aventis Pharma launches anti-rheumatic drug "Arava"Handok-Aventis Pharma has newly launched Arava (leflunomide), a new disease-modifying anti-rheumatic drug (DMARD) that reduces inflammation and slows disease progression of rheu...
|
Upward momentum of pharmaceutical firms shares likely to continue in April
Market analysts say that with increasing optimism on the possible commercialization of new drugs, combined with a foreign investors' buying spree, the index of pharmaceutical firms rose 3.07 percent in Februar...
Some drug company stocks rising due to SARS.
Amid a global panic with SARS breakout from the Southern China and the rumor that the plague also already landed in Korea, acute fears rapidly spreaded across the whole nation, in the meanwhile, causing some drug comp...
